Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

797
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
797
Imaging Studies VI: Voiding Cystourethrography and Cystography01:22

Imaging Studies VI: Voiding Cystourethrography and Cystography

2.6K
Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...
2.6K
Urinary Bladder01:23

Urinary Bladder

3.8K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
3.8K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

987
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
987
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.5K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.5K
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

1.2K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Male Hypogonadism and Lower Urinary Tract Symptoms: Testicular Volume as an Independent Predictor.

International neurourology journal·2026
Same author

Efficacy and Safety of Mirabegron and Tamsulosin Combination Therapy Compared to Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Results of a Multicenter, Randomized, Double-Blind, Phase III Clinical Trial.

The world journal of men's health·2025
Same author

A Multicenter, Randomized, Single-Blind Trial Evaluating a Multi-Porous Urethral Catheter with Continuous Local Ropivacaine Infusion for the Reduction of Postoperative Catheter-Related Bladder Discomfort.

Journal of clinical medicine·2025
Same author

Incidence of Depression and Anxiety in Kidney Cancer Survivors: A Nationwide Population-Based Cohort Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025
Same author

The impact of preoperative venous thromboembolism on patients undergoing TURBT: Perioperative outcomes and healthcare costs from US insurance claims data.

BJUI compass·2025
Same author

VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol.

BJU international·2024

Related Experiment Video

Updated: Feb 27, 2026

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

1.9K

Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms.

Kyung Jin Chung1, Benjamin I Chung1

  • 1Department of Urology, Stanford University School of Medicine, CA, USA.

International Neurourology Journal
|July 5, 2017
PubMed
Summary

New drugs for lower urinary tract symptoms (LUTS) show promise for treating benign prostatic hyperplasia and overactive bladder. This review offers urologists insights into current and future LUTS drug development.

Keywords:
Clinical trials as topicLower Urinary Tract SymptomsProstatic HyperplasiaUrinary Bladder, Overactive

More Related Videos

Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

2.8K
Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents
07:42

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents

Published on: April 25, 2017

10.1K

Related Experiment Videos

Last Updated: Feb 27, 2026

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

1.9K
Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

2.8K
Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents
07:42

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents

Published on: April 25, 2017

10.1K

Area of Science:

  • Urology
  • Pharmacology
  • Drug Development

Background:

  • Lower urinary tract symptoms (LUTS) represent a significant area of urological research.
  • Recent drug approvals for LUTS have spurred further interest in novel therapeutic agents.
  • Benign prostatic hyperplasia (BPH) and overactive bladder (OAB) are prevalent conditions driving market demand.

Purpose of the Study:

  • To review emerging drug candidates for BPH and OAB.
  • To provide urologists with an overview of the current drug development landscape for LUTS.
  • To highlight future directions in pharmacological treatments for LUTS.

Main Methods:

  • Literature review of new drugs in development for LUTS.
  • Focus on treatments targeting BPH and OAB.
  • Analysis of market relevance and research trends.

Main Results:

  • Several new drugs are under investigation for BPH and OAB.
  • The review identifies key areas of innovation in LUTS pharmacotherapy.
  • Market size and prevalence underscore the importance of these therapeutic targets.

Conclusions:

  • The pipeline for LUTS treatments is active, offering potential advancements for patients.
  • Continued research and development are crucial for addressing the unmet needs in urology.
  • Understanding the current drug development status is vital for urologists and researchers.